Treatment with Imfinzi for patients with advanced or metastatic NSCLC and limited physical performance status offered beneficial overall survival and maintained quality of life.
Researchers say an immune checkpoint inhibitor known as durvalumab performed well in a clinical trial for people with non-small cell lung cancer, even those with limited physical ability
Immunotherapy drug shows promise for treating non-small cell lung cancer onlinenews.com.pk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onlinenews.com.pk Daily Mail and Mail on Sunday newspapers.
Research: Immunotherapy Drug Safe for Weak Lung Cancer Patients miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.